Sartorius AG
OTC:SARTF
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| DE |
|
Sartorius AG
XETRA:SRT
|
12.9B EUR |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
189.6B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
138.8B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
132.5B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
115.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58.8B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46.4B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.8B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.4B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
39B USD |
Loading...
|
Market Distribution
| Min | -222 027.4% |
| 30th Percentile | -2% |
| Median | 2.2% |
| 70th Percentile | 6% |
| Max | 85 055.6% |
Other Profitability Ratios
Sartorius AG
Glance View
Sartorius AG, a formidable player in the life sciences industry, has been weaving the fabric of innovation within the biotechnology sector for over a century. Originating in 1870 as a precision mechanics workshop in Göttingen, Germany, the company has blossomed into a global powerhouse in the biopharmaceutical and laboratory equipment market. Central to Sartorius's operations is its focus on providing cutting-edge solutions that streamline lab processes and enhance productivity. By offering essential products like bioreactors and cell culture media, Sartorius plays a pivotal role in accelerating research and production processes for pharmaceutical companies worldwide. Underpinning Sartorius's financial success is its dual-pronged strategy: the Bioprocess Solutions division and the Lab Products & Services division. The Bioprocess Solutions wing caters to the production needs of biopharmaceuticals, delivering equipment and technologies crucial for manufacturing therapies and vaccines. Meanwhile, the Lab Products & Services division offers an array of instruments and consumables pivotal for research and quality control. This strategic alignment allows Sartorius to maintain robust growth by capturing value from both research and industrial production stages in biotech. With a well-orchestrated focus on innovation and expansion, Sartorius has cemented its role as a critical enabler in the biopharmaceutical value chain, continually driving developments that shape the future of medicine.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Sartorius AG is 3.8%, which is below its 3-year median of 5.8%.
Over the last 3 years, Sartorius AG’s Net Margin has decreased from 13.6% to 3.8%. During this period, it reached a low of 2.3% on Jun 30, 2024 and a high of 16.2% on Dec 31, 2022.